Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1997 1
1998 3
2000 1
2009 1
2016 2
2017 2
2018 2
2019 1
2020 2
2021 3
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

18 results
Results by year
Filters applied: . Clear all
Page 1
Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19.
Gritti G, Raimondi F, Bottazzi B, Ripamonti D, Riva I, Landi F, Alborghetti L, Frigeni M, Damiani M, Micò C, Fagiuoli S, Lorini FL, Gandini L, Novelli L, Morgan JP, Owens BMJ, Kanhai KJK, Reljanovic GT, Rizzi M, Di Marco F, Mantovani A, Rambaldi A. Gritti G, et al. Among authors: kanhai kjk. Leukemia. 2021 Sep;35(9):2710-2714. doi: 10.1038/s41375-021-01299-x. Epub 2021 May 24. Leukemia. 2021. PMID: 34031531 Free PMC article. No abstract available.
Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19.
Gritti G, Raimondi F, Bottazzi B, Ripamonti D, Riva I, Landi F, Alborghetti L, Frigeni M, Damiani M, Micò C, Fagiuoli S, Lorini FL, Gandini L, Novelli L, Morgan JP, Owens BMJ, Kanhai KJK, Reljanovic GT, Rizzi M, Di Marco F, Mantovani A, Rambaldi A. Gritti G, et al. Among authors: kanhai kjk. Leukemia. 2021 Sep;35(9):2734. doi: 10.1038/s41375-021-01329-8. Leukemia. 2021. PMID: 34183767 Free PMC article. No abstract available.
Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial.
Recourt K, van der Aart J, Jacobs G, de Kam M, Drevets W, van Nueten L, Kanhai K, Siebenga P, Zuiker R, Ravenstijn P, Timmers M, van Gerven J, de Boer P. Recourt K, et al. Among authors: kanhai k. J Psychopharmacol. 2020 Sep;34(9):1030-1042. doi: 10.1177/0269881120914206. Epub 2020 Apr 4. J Psychopharmacol. 2020. PMID: 32248747 Clinical Trial.
Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial.
Kanhai KMS, Nij Bijvank JA, Wagenaar YL, Klaassen ES, Lim K, Bergheanu SC, Petzold A, Verma A, Hesterman J, Wattjes MP, Uitdehaag BMJ, van Rijn LJ, Groeneveld GJ. Kanhai KMS, et al. CNS Neurosci Ther. 2019 Jun;25(6):697-703. doi: 10.1111/cns.13096. Epub 2019 Feb 12. CNS Neurosci Ther. 2019. PMID: 30756475 Free PMC article. Clinical Trial.
Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahydrocannabinol in Patients WithProgressive Multiple Sclerosis.
van Amerongen G, Kanhai K, Baakman AC, Heuberger J, Klaassen E, Beumer TL, Strijers RLM, Killestein J, van Gerven J, Cohen A, Groeneveld GJ. van Amerongen G, et al. Among authors: kanhai k. Clin Ther. 2018 Sep;40(9):1467-1482. doi: 10.1016/j.clinthera.2017.01.016. Epub 2017 Feb 9. Clin Ther. 2018. PMID: 28189366 Clinical Trial.
Glutathione-PEGylated liposomal methylprednisolone in comparison to free methylprednisolone: slow release characteristics and prolonged lymphocyte depression in a first-in-human study.
Kanhai KMS, Zuiker RGJA, Stavrakaki I, Gladdines W, Gaillard PJ, Klaassen ES, Groeneveld GJ. Kanhai KMS, et al. Br J Clin Pharmacol. 2018 May;84(5):1020-1028. doi: 10.1111/bcp.13525. Epub 2018 Mar 9. Br J Clin Pharmacol. 2018. PMID: 29385232 Free PMC article. Clinical Trial.
18 results